Fundraising FoxTopspin Partners — 2013 Investments
1 investments dated 2013 · listed companies and verified rows first · show all
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersOUP (Osage University Partners)Sanderling VenturesSanofi Ventures+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.